Social Sciences · Demography
1998 Nov;46(4): \n \n \n \n Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor.
SASO, Luciano, LEONE MG, SORRENTINO C, GIACOMELLI S, SILVESTRINI B, GRIMA J, LI JC, SAMY E, MRUK D, CHENG CY
See on the mapAbstract
Prostaglandin D synthetase (PGD-S; prostaglandin-H2 D-isomerase, EC 5,3,99,2), a \n30 kDa glycoprotein also known as beta-trace protein that catalyzes the formation \nof prostaglandin D2 (PGD2) from PGH2, was purified to apparent homogeneity from \nhuman cerebrospinal fluid (CSF) using a two-step procedure involving HPLC on a \nVydac C8 reversed-phase column and high performance electrophoresis \nchromatography (HPEC) using a 10% T SDS-polyacrylamide gel. The purity of PGD-S \nisolated from CSF was confirmed by silver stained SDS-polyacrylamide gel and \ndirect protein microsequencing (NH2-APEAQVSVQPNFQ). A highly specific polyclonal \nantibody was prepared against this protein for immunoassay development. Using an \nELISA, it was found that the concentration of PGD-S in CSF did not alter \nsignificantly in different pathological conditions of the central nervous system \n(CNS). These include dementia (n = 9), hydrocephalus (n = 4), neuropathy (n = \n11), optic neuritis (n = 4), multiple sclerosis (n = 11), and demyelinating \nsyndrome (n = 11), when compared to normal individuals (n = 12); however, the \nlevel of PGD-S in the CSF obtained from patients with brain tumor (n = 11), was \nreduced by as much as 2-fold when compared to control samples (n = 12) \nillustrating PGD-S is a potentially useful marker for brain tumor.